CD70 Protein (AA 39-193)

N° du produit ABIN2666755

Cette protéine Recombinant CD70 est produite dans CHO Cells.

Aperçu rapide pour CD70 Protein (AA 39-193) (ABIN2666755)

Antigène: CD70 (CD70 Molecule (CD70))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: CHO Cells

Application: Flow Cytometry (FACS), Functional Studies (Func), Immunohistochemistry (IHC)

Pureté: > 90 % , as determined by Coomassie stained SDS-PAGE.

Détail du produit

Attributs du protein: AA 39-193

Stérilité: 0.22 μm filtered

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: Human CD27L induces proliferation of PHA-activated human T cells in a dose dependent manner. The ED50 is less than 1.0 μg/mL. Results may vary depending on human donor and dose of PHA.

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Détail du antigène

Antigène: CD70 (CD70 Molecule (CD70))

Autre désignation: CD27L

Sujet: CD27L is a 50 kD type II transmembrane glycoprotein and member of the tumor necrosis factor superfamily. Human CD27L and its mouse counterpart share about 56 % sequence homology. The interaction of CD27L and CD27, a protein of the TNF receptor superfamily expressed on NK cells and subsets of T and B cells, provides co-stimulatory signals that are required for T cell proliferation, clonal expansion and development of effector T cells. CD27L-CD27 interaction on mouse B cells, on the other hand, has been shown to inhibit terminal differentiation of B cells into plasma cells. CD27L expression in mice is induced by B cell receptor activation in B cells, and at low levels by T cell receptor activation in T cells. CD27 interaction with recombinant soluble CD27L protein (sCD27L), showed that sCD27L enhanced IFN-γ secretion by CD56 (bright) NK cells in the presence of IL-12, and these NK cells were able to suppress HCV replication. Also, CD8+ T cells stimulated with sCD27L in the presence of antigen (Ag) showed enhanced proliferation and production of IL-2 and IFN-γ in vitro. In addition, administration of Ag and sCD27L induced expansion of Ag-specific CD8+ T cells in vivo. Data suggestes that sCD27L is a potent stimulator of antiglioma immune responses that depend on CD8+ T cells, therefore, sCD27L might be a good candidate as adjuvant in immunotherapy trials for glioblastoma.

Poids moléculaire: The 176 amino acid recombinant protein has a predicted molecular mass of approximately 19.3 kDa. The protein migrates at about 35 kDa in DTT-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is His.

Pathways: Cancer Immune Checkpoints